The core goal of Nucelis is to consistently deliver high-value, performance-focused and sustainably-sourced ingredient solutions to the personal care, nutrition and flavor and fragrance markets. We accomplish this by leveraging our proprietary, non-transgenic gene editing technologies and integrated production development platform.
This platform has demonstrated unique versatility with the development and production of our premium emollient, squalane, as well as our highly valued nutritional products - Vitamin D2, ergosterol and Yarrowia Flour ingredients.
Dr. O'Connor comes to Nucelis with nearly 30 years of management and research experience in the specialty chemicals business. Before joining Nucelis, he worked with Chemtura Corporation, where he held several key management positions including Vice President Plastic Additives Group, Vice President Strategy, and finally President of Petroleum Additives. He worked at Crompton Corporation prior to its merger with Great Lakes Corporation to form Chemtura, and worked at Adibis, a subsidiary of BP Chemicals in the United Kingdom before relocating to join Witco at its World Headquarters in the United States in 1994.
Dr. O'Connor is an inventor on over 25 U.S. patents, and has authored numerous scientific and product promotional papers. He received both his Ph.D. and B.Sc. Honours in Chemistry from the University of Bristol School of Chemistry.
Janine brings over 25 years management experience in corporate finance, business development and commercial operations, with an extensive background in financing via equity transactions, corporate and business development transactions, product commercialization, fundraising and debt structuring to Nucelis. As Vice President of Business Development, Janine leads all of the commercial operations efforts at Nucelis.
Prior to joining Nucelis, Janine was an Operational Consultant at Summit Consulting, where she acted as Chief Financial Officer and Chief Business Officer for several life science, industrial biotechnology and technology clients. While there, she was a key leader in building, integrating and leading all operational and financial aspects of the companies she worked with, in addition to negotiating multi-million dollar distribution, product supply, commercial production, and product licensing and research collaborations and leading the successful sale of one company. Previously she was Chief Financial Officer at PaxVax, a privately held global specialty vaccines company, and CFO at Genicon Sciences and Applied Molecular Evolution.
Janine holds an M.B.A. in Finance from Saint Joseph’s University and a B.A. in Economics and Business Administration from Ursinus College.
Board of Advisors
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.
He currently serves as an Entrepreneur In Residence to GE Ventures and is also on the boards of GeneNews Ltd. (a molecular diagnostics company) and Interpace Diagnostics (a molecular diagnostics company). He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).
Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.
Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets.
Dr. Walker's more than 30 years in agricultural biotechnology spans the development of the field.
As vice president of ValiGen, Dr. Walker was instrumental in transforming the Plant and Industrial Products Division, of which he was head, into what is now Cibus US LLC.
Prior to becoming President and CEO of Cibus US LLC, Dr. Walker held a variety of management positions at the Mycogen Corporation, ranging from business development, biotechnology research management and technology in-and-out-licensing.
Dr. Walker worked at Agrigenetics Company prior to its acquisition by Mycogen, and was a co-founder, director and vice president of research at agbiotech company Plant Genetics, Inc. (PGI).
Before founding PGI, Dr. Walker served in a variety of research capacities at Monsanto Co. and was a former vice chairman (1985) and chairman (1987) of the Gordon Conference in Plant Cell and Tissue Culture. He also was associate editor of Plant Cell Tissue and Organ Culture.
Dr. Walker received his Ph.D. in biology from Yale University and is a graduate of the College of Wooster.
Dr. Wochok is the retired CEO of PGP International, a grain and dairy based food ingredient company located in Woodland, Calif., and part of Associated British Foods, plc. He led that business for 15 years, achieving a nearly fivefold increase in revenues and consistent profitability. He currently is the President and Founder of The Wochok Group, LLC (www.wochokgroup.com), a management consulting business in Davis, Calif.
Prior to joining PGP in 1996, Dr. Wochok served for three years as Chairman and CEO of NURTURE, Inc., a specialty grain based Ingredients Company located in Missoula, Montana.
From 1989 to 1991, Dr. Wochok was President and COO of Calgene, Inc., where he was responsible for managing the company's five operating subsidiaries, product development, and human resources. From 1983 until its merger with Calgene in 1989, Dr. Wochok was the CEO of Plant Genetics, Inc., an ag-biotech company in Davis, Calif., which he took public in 1987 prior to merging with Calgene, Inc. in 1989.
Prior to 1983, Dr. Wochok was Business Development Manager in the New Ventures Department at Monsanto Company and a lead scientist for Weyerhaeuser Company.
In addition to his role with Nucelis, Dr. Wochok serves on the Board of Ag-Tech Accelerator and the Food Science and Technology Department of UC Davis, and is an advisor to the board of Cibus, LLC. He serves on the board of Grazix animal Health, Inc., and is the Chairman of the California Institute for Food and Agricultural Research.
Dr. Wochok began his career as a professor of biology at the University of Alabama, following a NIH funded postdoctoral position at Yale University. He received his Ph.D. in cell and developmental biology at the University of Connecticut as a NIH predoctoral fellow. He is the author of numerous scientific publications, business articles, and holds one patent.
Underlying our mission is a vision for changing the way the markets view fermentation-based ingredients. Our team believes in exploring nature's own production vehicles, (yeast, plants, bacteria, algae) to identify intriguing compounds and develop naturally-sourced ingredient solutions that mirror and are aligned with our environment and sustainability commitment.
Please contact us to find out more.